Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orphenadrine citrate + paracetamol
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bludol-Standpharm is a combination pharmaceutical product containing orphenadrine citrate and paracetamol (acetaminophen). It is primarily used as a skeletal muscle relaxant and analgesic for the treatment of painful musculoskeletal conditions, such as muscle spasms, strains, and tension-related pain. Orphenadrine citrate acts as a centrally acting muscle relaxant, likely through its activity as an NMDA receptor antagonist and its anticholinergic properties. Paracetamol provides complementary analgesic and antipyretic effects by inhibiting prostaglandin synthesis, primarily within the central nervous system. This combination is typically administered orally in tablet form and is marketed by Standpharm, a pharmaceutical company based in Pakistan.
- Brand names
- BludolBludol Forte
- Other names
- orphenadrine/paracetamol
02
Targets
HRH1 (Histamine H1 Receptor)NaV (Voltage-gated sodium channels)mAChR (Muscarinic acetylcholine receptors)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NMDAR (Glutamate receptor ionotropic, NMDA)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on orphenadrine citrate + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orphenadrine citrate + paracetamol.